Roth Capital Weighs in on Cryoport, Inc.’s Q2 2025 Earnings (NASDAQ:CYRX)

Cryoport, Inc. (NASDAQ:CYRX) – Equities research analysts at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Cryoport in a research note issued to investors on Wednesday, May 8th. Roth Capital analyst R. Baldry anticipates that the company will post earnings of ($0.31) per share for the quarter. The consensus estimate for Cryoport’s current full-year earnings is ($1.42) per share. Roth Capital also issued estimates for Cryoport’s Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.21) EPS.

Several other research analysts have also recently weighed in on CYRX. B. Riley cut Cryoport from a “buy” rating to a “neutral” rating and decreased their target price for the company from $22.00 to $19.00 in a research note on Friday, May 3rd. Stephens reissued an “equal weight” rating and set a $17.00 target price on shares of Cryoport in a research note on Wednesday, March 13th. UBS Group upped their price target on Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a report on Friday, March 15th. Jefferies Financial Group assumed coverage on Cryoport in a research note on Thursday, April 4th. They set a “buy” rating and a $21.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Cryoport in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $18.25.

Cryoport Stock Performance

CYRX opened at $13.20 on Thursday. Cryoport has a 1-year low of $9.00 and a 1-year high of $23.50. The company has a market capitalization of $648.96 million, a price-to-earnings ratio of -6.00 and a beta of 1.60. The business has a 50 day moving average price of $16.87 and a two-hundred day moving average price of $15.20. The company has a debt-to-equity ratio of 0.82, a current ratio of 11.73 and a quick ratio of 11.16.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). Cryoport had a negative net margin of 42.69% and a negative return on equity of 11.86%. The company had revenue of $54.59 million during the quarter, compared to the consensus estimate of $58.78 million. During the same quarter last year, the business earned ($0.16) earnings per share. The company’s revenue was down 13.1% on a year-over-year basis.

Insider Transactions at Cryoport

In related news, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $46,147.74. Following the completion of the sale, the chief executive officer now owns 692,182 shares of the company’s stock, valued at $12,140,872.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Jerrell Shelton sold 2,631 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $17.54, for a total transaction of $46,147.74. Following the transaction, the chief executive officer now owns 692,182 shares of the company’s stock, valued at $12,140,872.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ramkumar Mandalam sold 3,217 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $14.68, for a total transaction of $47,225.56. Following the completion of the sale, the director now directly owns 43,187 shares of the company’s stock, valued at $633,985.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,940 shares of company stock valued at $1,147,538. 10.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its position in shares of Cryoport by 1.0% in the first quarter. Conestoga Capital Advisors LLC now owns 71,417 shares of the company’s stock valued at $1,264,000 after purchasing an additional 690 shares during the period. Arizona State Retirement System lifted its position in Cryoport by 5.4% during the 4th quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock worth $212,000 after acquiring an additional 696 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Cryoport by 13.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock valued at $157,000 after purchasing an additional 1,395 shares during the last quarter. Natixis Investment Managers International increased its stake in shares of Cryoport by 61.5% in the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after purchasing an additional 1,727 shares during the period. Finally, Advisors Capital Management LLC lifted its position in shares of Cryoport by 2.5% during the 3rd quarter. Advisors Capital Management LLC now owns 78,993 shares of the company’s stock worth $1,083,000 after purchasing an additional 1,947 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.